Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Core Insights - Shattuck Labs, Inc. is developing SL-325, a high-affinity DR3 blocking antibody for the treatment of inflammatory bowel disease (IBD), with positive preclinical data indicating no toxicity or residual agonism in non-human primates [1][4][5] - The company plans to file an Investigational New Drug (IND) application in the third quarter of 2025, with Phase 1 clinical trials expected to commence later this year [1][4][5] Preclinical Data - SL-325 demonstrated complete and durable DR3 receptor occupancy at low doses in non-human primates, with no observed adverse effects or organ dysfunction [5][6] - The pharmacokinetic profile suggests extended dosing intervals in humans, with projected dosing of 1 mg/kg every two weeks for induction and 3 mg/kg every two weeks for maintenance [5][6] Mechanism of Action - Inhibition of the TL1A/DR3 signaling axis by SL-325 shows complete remission rates that match or exceed those of existing therapies, indicating a potentially more effective treatment option for IBD [2][4] - The antibody's design aims for a more complete blockade of the DR3/TL1A pathway compared to TL1A blocking antibodies, leveraging the higher expression of DR3 in IBD patients [2][4] Company Overview - Shattuck Labs specializes in developing treatments for autoimmune and inflammatory diseases, with a focus on novel therapeutics targeting TNF superfamily receptors [5][6] - The company operates from Austin, Texas, and Durham, North Carolina, and emphasizes its expertise in protein engineering [6]